Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Novartis

Revenues up 4% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis

3Q Revenues: $14.3 billion (+4%)

3Q Earnings: $2.3 billion (-6%)

YTD Revenues: $42.8 billion (+2%)

YTD Earnings: $7.2 billion (-2%)

Comments: Pharmaceutical sales were $7.9 billion in the quarter, up 1%, offset by generic competition for Diovan (-14% to $835 million). Oncology sales were $2.7 billion, up 2%, driven by Afinitor (+65% to $337 million), Tasigna (+25% to $315 million), Exjade (+9% to $212 million) and Sandostatin (+7% to $401 million), offset by Zometa (-66% to $104 million). The Primary Care franchise was up 7% to $1.8 billion driven by continued strong uptake of Galvus (+46% to $316 million) and Exforge (+11% to $359 million). The Neuroscience franchise was up 25% to $0.9 billion with growth from Gilenya (+63% to $518 million). The Ophthalmics franchise was down 2% to $0.6 billion, impacted by Lucentis (-1% to $581 million), which had a negative pricing impact. Sandoz sales were up 11% to $2.3 billion in the quarter. Alcon sales were up 3% to $2.5 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters